Click on image to view larger version.

Figure 2 Plasma Lp-PLA₂ Activity

The results are presented as geometric means with 95% confidence interval. All doses of darapladib produced highly significant inhibition of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) activity when compared with placebo at weeks 4 and 12 (p < 0.001).